PCI Pharma Services Enters Next Phase of Growth With Strategic Investment from Bain Capital, Kohlberg, and Mubadala

Contributed by: Business Wire

Logo

Tags

Health

Clinical Trials

Research

Pharmaceutical

Science

Biotechnology

PCI Pharma Services

More Like This

PCI Pharma Services is investing more than $365 million in infrastructure supporting the clinical and commercial-scale final assembly and packaging of drug-device combination products utilizing advanced drug delivery systems, with an emphasis on injectable formats. (Photo: Business Wire)

PCI Pharma Services Invests Over $365 Million in EU, US Facilities for Clinical and Commercial Supply of Advanced Drug Delivery and Drug-Device Combination Products

PCI becomes first drug product CDMO to navigate ICMRA multi-agency inspection process. (Photo: Business Wire)

PCI Pharma Services’ Bedford, New Hampshire Location Successfully Completes International Coalition of Medicines Regulatory Authorities Inspection

The report discloses PCI's performance, targets, and strategy to achieve nine identified impact categories. (Photo: Business Wire)

Leading CDMO PCI Pharma Services Releases Inaugural Comprehensive ESG Report

PCI Pharma Services enhances US manufacturing of prefilled syringes & cartridges through acquisition of Ajinomoto Althea.

Part of $1 Billion Investment Strategy, PCI Pharma Services Completes Acquisition of Ajinomoto Althea, Enhancing US Drug Product Manufacturing for Aseptic Filling of Prefilled Syringes & Cartridges

PCI Pharma Services to Acquire US-based Aseptic Fill-Finish CDMO Ajinomoto Althea.

PCI Pharma Services to Acquire US-based Aseptic Fill-Finish CDMO Ajinomoto Althea

Aldena Therapeutics Selects PCI Pharma Services to Manufacture and Distribute Innovative Investigational Treatment for Dermatological Diseases

PR Newswire associated0

Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan

Recipharm and PLG announce strategic partnership to accelerate development projects